The Science Behind an Impurity Reference Standard: How the Sinco Pharmaceutical Reference Standard R&D Team Translated Molecular Insight into an International Journal
The Science Behind an Impurity Reference Standard: How the Sinco Pharmaceutical Reference Standard R&D Team Translated Molecular Insight into an International Journal
The Development of SGLT Inhibitors: From Phlorizin to Modern TherapeuticsThe international review published by Sinco Pharmaceutical Reference Standard R&D Team lays bare the molecular logic of the "glin" class of drugs—from phlorizin all the way to dapagliflozin, empagliflozin...
New Arrivals Issue 027 | Impurities in Chronic Disease Drugs — Full Compliant Spectra to Safeguard R&D
New Arrivals Issue 027 | Impurities in Chronic Disease Drugs — Full Compliant Spectra to Safeguard R&D
IntroductionChronic diseases represent the largest segment of medication demand: approximately 450 millionpatients in China live with chronic conditions, which account for 88.5%of total deaths and over 70%of medical expenses. Hypertension, type 2 diabetes, overweight/obesity, and ...
New Product Express Issue 026 | Psychiatric Nervous System Drug Impurity Profiling: Paliperidone & Ziprasidone Impurity Reference Standards Expanded
New Product Express Issue 026 | Psychiatric Nervous System Drug Impurity Profiling: Paliperidone & Ziprasidone Impurity Reference Standards Expanded
Introduction: Why Is Impurity Control in Antipsychotic Drugs More Stringent?Introduction: Why Is Impurity Control in Antipsychotic Drugs More Stringent?Antipsychotic drugs can be classified into two categories based on receptor mechanisms. Typical antipsychotics (FGAs, first-gener...
New Arrivals Issue 028 | Impurities in Nervous System & Analgesia Drugs — Core Structures in Stock for Immediate Delivery Introduction
New Arrivals Issue 028 | Impurities in Nervous System & Analgesia Drugs — Core Structures in Stock for Immediate Delivery Introduction
IntroductionThe nervous system and analgesia therapeutic area represents one of the longest treatment cycles in pharmacotherapy: in China alone, over 40 million patients suffer from diabetic peripheral neuropathy, and over 3 million live with Parkinson's disease. Migraine, insomni...
New Product Express Issue 025 | Impurities of Four Core Cardiovascular Drugs Launched, Full Set of Compliant Spectra to Support R&D
New Product Express Issue 025 | Impurities of Four Core Cardiovascular Drugs Launched, Full Set of Compliant Spectra to Support R&D
Introduction: Impurity research of cardiovascular drugs: from "large quantity" to "high quality"Cardiovascular disease has long ranked first among global causes of death, and the market scale of related drugs is huge. From classic β-receptor blockers to first-line antihypertensive...
Overcoming Synthetic Challenges: Custom Synthesis and Structural Elucidation of Upadacitinib Impurity 15
Overcoming Synthetic Challenges: Custom Synthesis and Structural Elucidation of Upadacitinib Impurity 15
ForewordUpatinib (Upadacitinib, Figure 1) is a highly efficient and selective JAK1 inhibitor. In biochemical assays, its selectivity for JAK-1 is 74 times higher than that for JAK-2 (involved in erythropoiesis) and 58 times higher than that for JAK-3 (involved in immune surveillan...
New Product Express Issue 024 | New Impurities for Antiviral and Clinically Common Drugs Launched, Full Set of Compliance Spectra to Safeguard R&D
New Product Express Issue 024 | New Impurities for Antiviral and Clinically Common Drugs Launched, Full Set of Compliance Spectra to Safeguard R&D
Introduction: The "New Challenges" of High-Frequency Drug ImpuritiesFrom the antiviral drug Peramivir used during flu season, to the new-generation acid-suppressing drug Tegoprazan; from the classic glucocorticoid Hydrocortisone, to the monobactam antibiotic Aztreonam, and the wel...
New Product Express Issue 023 | CNS Neuropsychiatric Drug Impurities New, Full Set of Compliance Map Escort Research and Development
New Product Express Issue 023 | CNS Neuropsychiatric Drug Impurities New, Full Set of Compliance Map Escort Research and Development
Introduction: The "Invisible Barrier" Behind a $130B MarketAccording to IQVIA, the global CNS therapeutics market surpassed $130 billion in 2025, growing at a CAGR exceeding 6%. However, impurity profiling in this field faces hurdles far exceeding those of standard small molecules...
New Product Express Issue 022 | New Oncology-Targeted & Immunomodulatory Impurities Added — Full Compliant Certificates to Empower Your R&D
New Product Express Issue 022 | New Oncology-Targeted & Immunomodulatory Impurities Added — Full Compliant Certificates to Empower Your R&D
Lead-in: The "Purity Battle" of Targeted TherapiesIn the R&D landscape of innovative and high-end generic drugs, API (Active Pharmaceutical Ingredient) quality control remains the decisive factor between success and failure. As NMPA and FDA requirements for genotoxic impuritie...
New Arrivals Issue 021 | Four hot tracks of impurities just launched, full set of compliant charts to support R&D
New Arrivals Issue 021 | Four hot tracks of impurities just launched, full set of compliant charts to support R&D
New Arrivals Issue 021 | Four hot tracks of impurities just launched, full set of compliant charts to support R&D